Precedence Research recently published a report on “Biopharmaceutical CMO and CRO Market (By Service: Contract Manufacturing and Contract Research; By Source: Mammalian and Non-Mammalian; By Product Type: Biologics and Biosimilars) – Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2021 – 2030”, The global biopharmaceutical CMO and CRO market size is projected to reach USD 29.1 billion by 2030 from an estimated USD 59.4 billion in 2020, at a CAGR of 7.4% from 2021 – 2030.
The market revenue/volume with the help of widespread quantitative and qualitative insights, and forecasts of the market. This report presents breakdown of market into forthcoming and niche segments. Additionally, this research study gauges market revenue growth and its drift at global, regional, and country from 2017 to 2030. This research report evaluates biopharmaceutical CMO and CRO market on a global and regional level. It offers thorough analysis of market status, growth and forecast of the global biopharmaceutical CMO and CRO market for the period from 2017 to 2030.
We customize your report according to your research need. REQUEST CUSTOMIZED COPY OF REPORT (Including TOC, List of Tables & Figures, and Chart) @ https://www.precedenceresearch.com/customization/1289
The biopharmaceutical CMO and CRO is an integral part of the biopharmaceutical industry. The CMO and CRO are directly linked and influenced by the biopharmaceutical industry. CMO stands for contract manufacturing organizations that sets up manufacturing plants and produces biopharmaceutical products on large scale on contract basis. These organizations are manufacturing specialists that saves cost and time of the contractor and provides efficient output. The CRO refers to the contract research organizations that undertake the task of various research and developmental activities assigned by the contractors and helps in the development of new and innovative drugs. The rising demand for the biopharmaceutical drugs among the consumers has contributed to the rapid growth of the biopharmaceutical industry. Biopharmaceutical is rapidly growing globally and it alone accounts for over 20% of the total pharmaceutical industry. Growing investments and manufacturing contracts by the small and medium sized pharma industry players is propelling the growth of the CMO and CRO in the market significantly.
Crucial factors accountable for market growth are:
Scope of the Biopharmaceutical CMO and CRO Market Report
| Report Coverage | Details |
| Market Size in 2030 | USD 59.4 Billion |
| Growth Rate from 2021 to 2030 | CAGR of 7.4% |
| Base Year | 2021 |
| Forecast Period | 2021 to 2030 |
| Segments Covered | Product Type, Source Type, Service Type |
| Regional Scope | North America, APAC, Europe, Latin America, MEAN, Rest of the World |
| Companies Mentioned | TOYOBO Co. Ltd., Samsung Biologics, LabCorp, Lonza, BoehringerIngelheim, Patheon, CMC Biologics, JRS Pharma, PRA Health Sciences, RentschlerBiotechnologie, FUJIFILM Diosynth Biotechnologies, WuXi Biologics |
Regional Snapshots
North America is the leading biopharmaceutical CMO and CRO market. The US accounts for around 33.33% of the global biopharmaceutical CMO market and is also the leader in biopharmaceutical CRO market. As per the Pharmaceutical Research and Manufacturers Association, US has the property rights on majority of the new medicines. North America is characterized by supportive setting for the commercialization and development of medicines, rewards to the developers in the form of intellectual property rights, and supportive regulatory framework for the biopharmaceuticals. This helps in attracting capital investments in North America region for the development of biopharmaceutical companies. This is a significant growth factor that boosts the growth and development of the biopharmaceutical CMO and CRO market in the region.
Asia Pacific is estimated to be the fastest-growing region, owing to enhanced regulatory framework regarding the biopharmaceuticals, greater supply of capital, and support from the government. In South Korea, the Samsung Biologics witnessed a spike in its sales by 56% in 2017. Further, the Celltrion Group of South Korea acquired European Medicines Agency approval for it biosimilar product called Herzuma, in 2018. Further, in India, Biocon received FDA approval for its biosimilar product called Ogivri in 2017. China, the second largest market for the biopharmaceuticals is attracting FDIs for setting up manufacturing units that exponentially propels the biopharmaceutical CMO and CRO market growth in Asia Pacific region.
Report Highlights
Drivers
The global biopharmaceutical CMO and CRO market is primarily driven by the increasing popularity and increasing investments by the key players in the biopharmaceutical industry for the development of cost-effective and innovative drugs.
Restraints
The lack of proper healthcare infrastructure in underdeveloped economies, lack of awareness regarding technologically advanced biopharma products, and high costs involved are the major factors that may hamper the market growth.
Opportunities
The growing research and development activities carried on by the key market players to develop effective drugs and medicines for various serious illnesses and disease like cancer may open up new opportunities in the upcoming future.
Challenges
Lack of adequate capital in the hands of the small pharmaceutical developers who have interests in shifting towards biopharmaceuticals is a major challenge that may slow down the growth of the global biopharmaceutical CMO and CRO market.
Recent Developments
Scope of the Study
This biopharmaceutical CMO and CRO market report studies market dynamics, status and outlook especially in North America, Europe and Asia-Pacific, Latin America, Middle East and Africa. This research report offers scenario and forecast (revenue/volume), and categorizes market by players, type, application, and region. This report also studies global market prominence, competitive landscape, market share, growth rate market dynamics such as drivers, restraints and opportunities, and distributors and sales channel.
This research study also integrates Industry Chain analysis and Porter’s Five Forces Analysis. Further, this report offers competitive scenario which comprises collaborations, market concentration rate and expansions, mergers & acquisitions undertaken by companies.
Key Players:
This report also provides detailed company profiles of the key market players. This research report also highlights the competitive landscape of the biopharmaceutical CMO and CRO market and ranks noticeable companies as per their occurrence in diverse regions across globe and crucial developments initiated by them in the market space. This research study also tracks and evaluates competitive developments, such as collaborations, partnerships, and agreements, mergers and acquisitions; novel product introductions and developments, promotion strategies and Research and Development (R&D) activities in the marketplace. The competitive profiling of these players includes business and financial overview, gross margin, production, sales, and recent developments which can aid in assessing competition in the market.
Some of the prominent players in the biopharmaceutical CMO and CRO market include:
Segments Covered in the Report
By Service
By Source
By Product
Key Points Covered in biopharmaceutical CMO and CRO market Study:
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Source Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global Biopharmaceutical CMO and CRO Market, By Product
7.1. Biopharmaceutical CMO and CRO Market, by Product Type, 2021-2030
7.1.1. Biologics (Vaccines, Monoclonal antibodies (MABs), Recombinant Proteins, Others)
7.1.1.1. Market Revenue and Forecast (2017-2030)
7.1.2. Biosimilars
7.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 8. Global Biopharmaceutical CMO and CRO Market, By Service
8.1. Biopharmaceutical CMO and CRO Market, by Service, 2021-2030
8.1.1. Contract Manufacturing (Process Development, Fill & Finish Operations, Analytical & QC studies, Packaging)
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Contract Research (Inflammation & Immunology, Cardiology, Oncology, Neuroscience, Others)
8.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Biopharmaceutical CMO and CRO Market, By Source
9.1. Biopharmaceutical CMO and CRO Market, by Source, 2021-2030
9.1.1. Mammalian
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Non-Mammalian
9.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Biopharmaceutical CMO and CRO Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Product (2017-2030)
10.1.2. Market Revenue and Forecast, by Service (2017-2030)
10.1.3. Market Revenue and Forecast, by Source (2017-2030)
10.1.4. U.S.
10.1.4.1. Market Revenue and Forecast, by Product (2017-2030)
10.1.4.2. Market Revenue and Forecast, by Service (2017-2030)
10.1.4.3. Market Revenue and Forecast, by Source (2017-2030)
10.1.5. Rest of North America
10.1.5.1. Market Revenue and Forecast, by Product (2017-2030)
10.1.5.2. Market Revenue and Forecast, by Service (2017-2030)
10.1.5.3. Market Revenue and Forecast, by Source (2017-2030)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Product (2017-2030)
10.2.2. Market Revenue and Forecast, by Service (2017-2030)
10.2.3. Market Revenue and Forecast, by Source (2017-2030)
10.2.4. UK
10.2.4.1. Market Revenue and Forecast, by Product (2017-2030)
10.2.4.2. Market Revenue and Forecast, by Service (2017-2030)
10.2.4.3. Market Revenue and Forecast, by Source (2017-2030)
10.2.5. Germany
10.2.5.1. Market Revenue and Forecast, by Product (2017-2030)
10.2.5.2. Market Revenue and Forecast, by Service (2017-2030)
10.2.5.3. Market Revenue and Forecast, by Source (2017-2030)
10.2.6. France
10.2.6.1. Market Revenue and Forecast, by Product (2017-2030)
10.2.6.2. Market Revenue and Forecast, by Service (2017-2030)
10.2.6.3. Market Revenue and Forecast, by Source (2017-2030)
10.2.7. Rest of Europe
10.2.7.1. Market Revenue and Forecast, by Product (2017-2030)
10.2.7.2. Market Revenue and Forecast, by Service (2017-2030)
10.2.7.3. Market Revenue and Forecast, by Source (2017-2030)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Product (2017-2030)
10.3.2. Market Revenue and Forecast, by Service (2017-2030)
10.3.3. Market Revenue and Forecast, by Source (2017-2030)
10.3.4. India
10.3.4.1. Market Revenue and Forecast, by Product (2017-2030)
10.3.4.2. Market Revenue and Forecast, by Service (2017-2030)
10.3.4.3. Market Revenue and Forecast, by Source (2017-2030)
10.3.5. China
10.3.5.1. Market Revenue and Forecast, by Product (2017-2030)
10.3.5.2. Market Revenue and Forecast, by Service (2017-2030)
10.3.5.3. Market Revenue and Forecast, by Source (2017-2030)
10.3.6. Japan
10.3.6.1. Market Revenue and Forecast, by Product (2017-2030)
10.3.6.2. Market Revenue and Forecast, by Service (2017-2030)
10.3.6.3. Market Revenue and Forecast, by Source (2017-2030)
10.3.7. Rest of APAC
10.3.7.1. Market Revenue and Forecast, by Product (2017-2030)
10.3.7.2. Market Revenue and Forecast, by Service (2017-2030)
10.3.7.3. Market Revenue and Forecast, by Source (2017-2030)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Product (2017-2030)
10.4.2. Market Revenue and Forecast, by Service (2017-2030)
10.4.3. Market Revenue and Forecast, by Source (2017-2030)
10.4.4. GCC
10.4.4.1. Market Revenue and Forecast, by Product (2017-2030)
10.4.4.2. Market Revenue and Forecast, by Service (2017-2030)
10.4.4.3. Market Revenue and Forecast, by Source (2017-2030)
10.4.5. North Africa
10.4.5.1. Market Revenue and Forecast, by Product (2017-2030)
10.4.5.2. Market Revenue and Forecast, by Service (2017-2030)
10.4.5.3. Market Revenue and Forecast, by Source (2017-2030)
10.4.6. South Africa
10.4.6.1. Market Revenue and Forecast, by Product (2017-2030)
10.4.6.2. Market Revenue and Forecast, by Service (2017-2030)
10.4.6.3. Market Revenue and Forecast, by Source (2017-2030)
10.4.7. Rest of MEA
10.4.7.1. Market Revenue and Forecast, by Product (2017-2030)
10.4.7.2. Market Revenue and Forecast, by Service (2017-2030)
10.4.7.3. Market Revenue and Forecast, by Source (2017-2030)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Product (2017-2030)
10.5.2. Market Revenue and Forecast, by Service (2017-2030)
10.5.3. Market Revenue and Forecast, by Source (2017-2030)
10.5.4. Brazil
10.5.4.1. Market Revenue and Forecast, by Product (2017-2030)
10.5.4.2. Market Revenue and Forecast, by Service (2017-2030)
10.5.4.3. Market Revenue and Forecast, by Source (2017-2030)
10.5.5. Rest of LATAM
10.5.5.1. Market Revenue and Forecast, by Product (2017-2030)
10.5.5.2. Market Revenue and Forecast, by Service (2017-2030)
10.5.5.3. Market Revenue and Forecast, by Source (2017-2030)
Chapter 11. Company Profiles
11.1. Lonza
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. JRS Pharma
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Samsung Biologics
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. CMC Biologics
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. TOYOBO Co. Ltd.
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. RentschlerBiotechnologie
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. FUJIFILM Diosynth Biotechnologies
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. WuXi Biologics
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Patheon
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. BoehringerIngelheim
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
11.11. PRA Health Sciences
11.11.1. Company Overview
11.11.2. Product Offerings
11.11.3. Financial Performance
11.11.4. Recent Initiatives
11.12. LabCorp
11.12.1. Company Overview
11.12.2. Product Offerings
11.12.3. Financial Performance
11.12.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms
Buy Full Research Report (Single User License US$ 4500) @ https://www.precedenceresearch.com/checkout/1289
About Us
Precedence Research is a worldwide market research and consulting organization. We give unmatched nature of offering to our customers present all around the globe across industry verticals. Precedence Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings. We are obliged to serve our different client base present over the enterprises of medicinal services, healthcare, innovation, next-gen technologies, semi-conductors, chemicals, automotive, and aerospace & defense, among different ventures present globally.
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
Web: https://www.precedenceresearch.com
Blog: https://precedenceresearchnews.wordpress.com
Follow us on LinkedIn | Twitter | Facebook
Precedence Research recently published a report on “Drug of Abuse Testing Market (By Drug Type: Alcohol, Cocaine, Marijuana/Cannabis, LSD, Opioids,… Read More
Precedence Research recently published a report on “Digital Signage Market (By Component: Hardware, Software, Services; By Technology: LCD, LED, Projection;… Read More
Precedence Research recently published a report on “Beverage Packaging Market (By Material: Metal, Plastic, Glass, and Others; By Product: Bottles,… Read More
Precedence Research recently published a report on “Paper Cups Market (By type: Hot Paper Cups and Cold Paper Cups; By… Read More
Precedence Research recently published a report on “Fire Protection System Market (By Product: Fire Detection, Fire Suppression, Fire Response, Fire… Read More
This website uses cookies.